Thong Q. Le is a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation.
Mr. Le focuses on investment opportunities in biopharmaceuticals, medical devices, enterprise software and advanced materials. Since joining WRF Capital, he has played a significant role in the early sourcing, financing, and development of numerous start-up companies. He has worked closely with the management teams and boards of Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO.L), Lumera (NasdaqNM:LMRA), Performant (acquired by Mercury Interactive), and Pathway Medical Technologies (acquired by MEDRAD, Inc. affiliate of Bayer HealthCare). He is currently a Director of Accelerator, Acylin Therapeutics, ARZEDA, Groove Biopharma, and Oncofactor, and is a Board Observer at Alder Biopharmaceuticals, Cardeas Pharma, Hyperion Therapeutics, Uptake Medical, and VLST Corp.
Prior to joining WRF Capital, Mr. Le was the founder, president and chief executive officer of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc., where his clients included Fortune 500 companies, entrepreneurial teams, and top-tier venture capital firms. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures.
Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in economics and government from Harvard University. He currently serves on the executive boards of the Evergreen Venture Capital Association (EVCA), the Washington Biotechnology & Biomedical Association (Chairman), and the Washington Global Health Fund (Director and Treasurer).
This Friday the Washington Biotechnology & Biomedical Association (WBBA) will release findings from its 2010 Economic Impact Report at their Governor’s Life Sciences Summit and WBBA Annual Meeting. With the sometimes... Read more »